My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY:BSX)

98.31 +0.17 (+0.17%)
Streaming Delayed Price Updated: 2:28 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
BSX Q2 Deep Dive: Cardiovascular Momentum, New Technologies, and Global Expansion Shape Outlook
Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter’s... 
Via StockStory
Boston Sci Q2 Revenue Up 23 Percent
Via The Motley Fool
Topics Economy World Trade
Why Boston Scientific (BSX) Stock Is Up Today
Shares of medical device company Boston Scientific (NYSE:BSX) jumped 4.2% in the afternoon session after the company reported second-quarter financial results that surpassed Wall Street expectations... 
Via StockStory
Earnings Scheduled For July 23, 2025
 
Via Benzinga
Is Boston Scientific Gaining or Losing Market Support?
 
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Stocks Jump On Trump's Trade Deal Deluge Ahead Of Big Tech Earnings: What's Moving Markets Wednesday?
A wave of U.S. trade deals with key allies over the past 24 hours reignited Wall Street's rally and boosted investor risk appetite across global markets. 
Via Benzinga
Topics Government
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance
Boston Scientific beats Q2 estimates, posts 22.8% revenue growth, and raises full-year outlook on strong cardiovascular and MedSurg performance. 
Via Benzinga
P/E Ratio Insights for Boston Scientific
 
Via Benzinga
Boston Scientific Eyes Breakout On Strong Second Quarter, Guidance
The company issued a positive outlook for 2025 that includes better-than-expected sales growth and adjusted profit. 
Via Investor's Business Daily
Boston Scientific (NYSE:BSX) Reports Bullish Q2, Guides for Strong Sales Next Quarter
Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter’s... 
Via StockStory
What To Expect From Boston Scientific’s (BSX) Q2 Earnings
Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
BOSTON SCIENTIFIC CORP (NYSE:BSX) – A Strong Contender in Growth and Momentum Investing
Boston Scientific Corp (NYSE:BSX) shows strong technical and growth momentum, meeting Minervini Trend Template criteria with solid earnings and revenue expansion. A potential breakout candidate for... 
Via Chartmill
BOSTON SCIENTIFIC CORP (NYSE:BSX) - A Strong Technical Setup in the Medical Device Sector
Boston Scientific Corp (NYSE:BSX) shows strong technicals and a high-quality setup, making it a breakout candidate. The stock's consolidation near resistance and institutional support suggest potential... 
Via Chartmill
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
BOSTON SCIENTIFIC CORP (NYSE:BSX) – A High Growth Momentum Stock with Strong Technical Setup
BOSTON SCIENTIFIC CORP (NYSE:BSX) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has solid EPS growth, margin expansion, and... 
Via Chartmill
$100 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Large-Cap Stock for Long-Term Investors and 2 to Ignore
Via StockStory
1 Safe-and-Steady Stock to Research Further and 2 to Turn Down
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
BOSTON SCIENTIFIC CORP (NYSE:BSX) – A Strong Contender in Growth and Momentum
Boston Scientific Corp (NYSE:BSX) shows strong technical and fundamental growth, fitting Minervini’s trend template with high earnings momentum and improving margins. A top pick for momentum... 
Via Chartmill
BOSTON SCIENTIFIC CORP (NYSE:BSX) – A High Growth Momentum Stock with Strong Technical Setup
Boston Scientific Corp (NYSE:BSX) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has solid support levels and consolidation... 
Via Chartmill
1 Growth Stock with All-Star Potential and 2 to Keep Off Your Radar
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Leerink Initiates Boston Scientific Coverage With ‘Outperform’ Rating: Stock Rallies But Retail’s Not Overly Excited
The new price target of $118 represents an upside of over 18% from the stock’s closing price of $99.74 on Friday. 
Via Stocktwits
This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Deep Dive Into Boston Scientific Stock: Analyst Perspectives (13 Ratings)
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
$100 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
BOSTON SCIENTIFIC CORP (NYSE:BSX) – A High-Growth Momentum Stock with Strong Technical Setup
Boston Scientific Corp (NYSE:BSX) combines strong earnings momentum, expanding margins, and a bullish technical setup, making it a candidate for high-growth investors. 
Via Chartmill
3 Market-Beating Stocks with Competitive Advantages
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the... 
Via StockStory
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.